Review Exam 1 Fall 2026

Exam Structure and Administrative Overview

  • Required materials include a dedicated non-programmable or approved scientific calculator; mobile devices are strictly prohibited.
  • The exam format comprises multiple-choice questions, matching sections, fill-in-the-blank items, short-answer responses, and clinical case studies.
  • Core subject coverage encompasses:
    • Appendix A (medical terminology and specialized metrics).
    • Chapter 2 and Table 2.1 definitions (clinical screening, symptom presentation, and stratification).
    • Chapter 12 and lecture modules on cardiovascular anatomy and physiology, atherosclerotic heart disease, pharmacology, behavior change models, SOAP documentation, and the clinical patient interview and physical examination.

Cardiovascular Anatomy, Physiology, and Hemodynamics

  • Cardiac vs. Skeletal Muscle Structural and Functional Comparison:

    • Similarities:
    • Both tissues contain striated muscle fibers organized into sarcomeres containing actin and myosin myofilaments.
    • Both require intracellular calcium ions (Ca2+Ca^{2+}) binding to troponin to displace tropomyosin and initiate the cross-bridge cycle.
    • Both depend heavily on aerobic metabolism and rich mitochondrial density for sustained adenosine triphosphate (ATPATP) generation.
    • Differences:
    • Involuntary vs. Voluntary Control: Cardiac muscle is involuntary, regulated by the autonomic nervous system and intrinsic pacemaker tissues; skeletal muscle is voluntary, driven by somatic motor neurons.
    • Intercellular Connections: Cardiac myocytes are branched and connected end-to-end via intercalated discs containing desmosomes (mechanical adhesion) and gap junctions (electrical coupling that creates a functional syncytium); skeletal muscle fibers are elongated, multi-nucleated, non-branching cylinders that act as independent motor units.
    • Action Potential Duration and Refractory Period: Cardiac action potentials are prolonged (200−300 ms200 - 300\,\text{ms}) due to a plateau phase caused by inward calcium influx via L-type calcium channels, preventing tetanic contractions; skeletal action potentials are brief (1−5 ms1 - 5\,\text{ms}) with a short refractory period allowing summation and tetanus.
    • Calcium Release Mechanism: Cardiac contraction uses calcium-induced calcium release (CICRCICR), where extracellular calcium influx triggers the ryanodine receptors on the sarcoplasmic reticulum (SRSR); skeletal muscle relies on direct mechanical coupling between voltage-sensing dihydropyridine receptors (DHPRDHPR) and ryanodine receptors on the SRSR.
    • Pacemaker Activity: Specific cardiac myocytes exhibit intrinsic autorhythmicity (spontaneous diastolic depolarization in the sinoatrial node, atrioventricular node, and Purkinje system); skeletal muscle requires external neural stimulation to depolarize.
  • Hemodynamic Indices and Mathematical Calculations:

    • Stroke Volume (SVSV):
    • Definition: The volume of blood ejected by the left ventricle in a single cardiac contraction.
    • Formula:       SV=EDV−ESVSV = EDV - ESV
    • Parameters:
      • EDVEDV is the End-Diastolic Volume (volume of blood in the ventricle at the end of diastole/filling, typically ≈120 mL\approx 120\,\text{mL} at rest).
      • ESVESV is the End-Systolic Volume (residual volume of blood left in the ventricle after systolic contraction, typically ≈50 mL\approx 50\,\text{mL} at rest).
    • Normal Resting Value: Approximately 70 mL70\,\text{mL}.
    • Ejection Fraction (EFEF):
    • Definition: The volumetric fraction of blood pumped out of the ventricle relative to the total end-diastolic volume, serving as a primary index of myocardial contractility.
    • Formula:       EF=(SVEDV)×100%EF = \left(\frac{SV}{EDV}\right) \times 100\%
    • Alternative Expression:       EF=(EDV−ESVEDV)×100%EF = \left(\frac{EDV - ESV}{EDV}\right) \times 100\%
    • Clinical Interpretation:
      • Normal range: 55%−70%55\% - 70\%
      • Mild dysfunction: 40%−54%40\% - 54\%
      • Moderate dysfunction: 30%−39%30\% - 39\%
      • Severe dysfunction / Heart Failure with Reduced Ejection Fraction (HFrEFHFrEF): <30%< 30\%
    • Preload:
    • Definition: The degree of stretch on the myocardial fibers at the end of ventricular diastole, directly determined by the volume and pressure within the ventricle immediately prior to contraction (EDVEDV or end-diastolic pressure).
    • Governing Principle: The Frank-Starling Law of the heart states that increased end-diastolic volume stretches myocardial sarcomeres toward their optimal length, increasing cross-bridge overlap and augmenting the force of contraction, which increases stroke volume.
    • Determinants: Venous return, total circulating blood volume, atrial contraction (atrial kick), ventricular compliance, and skeletal muscle pump activity.
    • Afterload:
    • Definition: The resistance or systemic tension against which the left ventricle must exert pressure to overcome the aortic valve pressure and eject blood during systole.
    • Determinants: Total peripheral resistance (TPRTPR) or systemic vascular resistance (SVRSVR), arterial compliance, aortic diameter, and systemic blood pressure.
    • Clinical Impact: Elevated afterload (e.g., chronic systemic hypertension, aortic stenosis) increases myocardial wall tension, elevates myocardial oxygen demand, decreases stroke volume, and promotes concentric left ventricular hypertrophy.
    • Myocardial Oxygen Consumption (MVO2MVO_2) and Rate Pressure Product (RPPRPP):
    • Definition: The actual volume of oxygen consumed by the myocardium to support its mechanical and metabolic workload.
    • Rate Pressure Product (RPPRPP) / Double Product: The non-invasive, direct clinical surrogate for estimating MVO2MVO_2.
    • Calculation Formula:       RPP=HR×SBPRPP = HR \times SBP
    • Standard Scaled Formula:       RPP=HR×SBP100RPP = \frac{HR \times SBP}{100}
    • Parameters:
      • HRHR is the Heart Rate expressed in beats per minute (bpm\text{bpm}).
      • SBPSBP is the Systolic Blood Pressure expressed in millimeters of mercury (mmHg\text{mmHg}).
    • Clinical Utility: Direct indicator of coronary circulatory load and ischemia. Angina or ischemic electrocardiographic changes (e.g., STST-segment depression) typically manifest at a reproducible RPPRPP threshold (ischemic threshold).

Coronary Artery Disease and Atherosclerosis

  • Definition and Etiology of Coronary Artery Disease (CADCAD):

    • A progressive pathological condition characterized by the accumulation of fibrofatty atherosclerotic plaques within the epicardial coronary arteries, producing luminal narrowing, impaired myocardial perfusion, and clinical manifestations ranging from stable angina to acute coronary syndromes (ACSACS).
  • Pathogenesis and Mechanism of Arterial Plaque Formation:

    • Endothelial Injury: Initiated by chronic mechanical or chemical damage to the vascular endothelium caused by shear stress from hypertension, circulating free radicals from tobacco smoke, hyperlipidemia (elevated oxidized LDL), diabetes-induced advanced glycation end-products (AGEsAGEs), and chronic systemic inflammation.
    • Endothelial Dysfunction and Infiltration: Damaged endothelial cells lose their regular antithrombotic and vasodilatory properties (decreased nitric oxide production) and express vascular cell adhesion molecules (VCAM−1VCAM-1). Circulating low-density lipoproteins (LDLLDL) cross the permeable endothelial boundary and become trapped within the tunica intima.
    • Lipid Oxidation and Monocyte Recruitment: Trapped subendothelial LDLLDL particles undergo oxidation (ox−LDLox-LDL). Endothelial cells release monocyte chemoattractant protein-1 (MCP−1MCP-1), driving circulating monocytes to adhere to the endothelium and migrate (diapedesis) into the intimal layer.
    • Foam Cell Formation: Intimal monocytes differentiate into macrophages, which express scavenger receptors to engulf large volumes of ox−LDLox-LDL. Engorged with lipid droplets, macrophages transform into foam cells.
    • Fatty Streak Development: Aggregated foam cells, along with associated T-lymphocytes, form visible yellow, flat streaks within the arterial wall, representing the earliest gross histological evidence of atherosclerosis.
    • Smooth Muscle Cell Migration and Proliferation: Platelet-derived growth factor (PDGFPDGF) and transforming growth factor-beta (TGF−βTGF-\beta) secreted by macrophages and damaged endothelial cells induce vascular smooth muscle cells (VSMCsVSMCs) to migrate from the tunica media into the tunica intima. These VSMCsVSMCs proliferate and synthesize extracellular matrix proteins (collagen, elastin, and proteoglycans).
    • Fibrous Plaque Formation: The deposition of collagen creates a firm fibrous cap that overlies a growing necrotic core composed of cellular debris, cholesterol crystals, and dead foam cells that have undergone apoptosis.
  • Structural and Morphological Characteristics of Plaques:

    • Stable Plaques:
    • Characterized by a thick, structurally dense fibrous cap rich in extracellular matrix proteins and smooth muscle cells.
    • Display a relatively small, contained lipid core with low levels of active inflammatory cells.
    • Result in fixed luminal obstruction leading to reproducible exertional symptoms (stable angina pectoris) that resolve with rest or nitroglycerin.
    • Vulnerable (Unstable) Plaques:
    • Characterized by a thin, fragile fibrous cap prone to mechanical disruption.
    • Feature an extensive, hyper-necrotic lipid core occupying greater than 30%−40%30\% - 40\% of plaque volume.
    • Display marked infiltration of active inflammatory cells (macrophages and T-cells) releasing matrix metalloproteinases (MMPsMMPs) that degrade collagen.
    • Pose a high risk of rupture or superficial erosion, which exposes underlying tissue factor and thrombogenic subendothelial matrix to circulating platelets, triggering immediate thrombosis, complete luminal occlusion, and acute myocardial infarction (AMIAMI).

Clinical Evaluation, Patient Interview, and Diagnostic Frameworks

  • Five Essential Components of Clinical Evaluation:

    • Medical History: Comprehensive review of past medical illnesses, prior cardiovascular events, family history of premature cardiovascular disease, surgical procedures, current prescription medications, dosages, over-the-counter supplements, allergies, and social history (tobacco, alcohol, recreational substance use, and physical activity levels).
    • Physical Examination: Systematic structural assessment including resting vital signs (bilateral blood pressures, resting heart rate, respiratory rate, oxygen saturation), cardiovascular auscultation (murmurs, gallops, rubs), pulmonary auscultation (crackles, wheezes), peripheral vascular assessment (palpation of carotid, radial, femoral, dorsalis pedis, and posterior tibial pulses), inspection for jugular venous distention (JVDJVD), and evaluation for pitting edema.
    • Laboratory Tests: Objective diagnostic blood profiles including fasting lipid panel (total cholesterol, HDLHDL, LDLLDL, triglycerides), fasting plasma glucose, hemoglobin A1cA_{1c} (HbA1cHbA_{1c}), comprehensive metabolic panel (serum creatinine, blood urea nitrogen, electrolytes, estimated glomerular filtration rate), complete blood count (CBCCBC), and specific cardiac biomarkers (high-sensitivity troponin, NT−proBNPNT-proBNP).
    • Diagnostic and Clinical Testing: Objective resting and functional assessments including 12-lead electrocardiography (ECGECG), diagnostic exercise stress testing (graded treadmill or cycle ergometry with gas analysis or nuclear imaging), resting and stress echocardiography, coronary computed tomography angiography (CCTACCTA), and diagnostic cardiac catheterization.
    • Risk Stratification and Clinical Decision-Making: Synthesis of clinical data into standardized disease classifications and pre-exercise risk categories, enabling the safe determination of exercise prescription parameters, hemodynamic monitoring requirements, and medical contraindications.
  • Major Signs or Symptoms Suggestive of Cardiovascular, Metabolic, or Renal Disease (ACSM Table 2.1 Criteria):

    • Pain; Discomfort (or other anginal equivalent) in the chest, neck, jaw, arms, or other areas: Caused by myocardial ischemia; manifests as pressure, squeezing, burning, heaviness, or constricting retrosternal discomfort radiating to the left shoulder, neck, mandible, or epigastrium.
    • Shortness of breath at rest or with mild exertion: Dyspnea that occurs unexpectedly at workloads well below anticipated aerobic thresholds, signaling pulmonary congestion, left ventricular dysfunction, or advanced respiratory pathology.
    • Dizziness or syncope: Fainting or sudden loss of consciousness caused by transient cerebral hypoperfusion, frequently resulting from severe cardiac output reduction, structural aortic stenosis, severe hypertrophic cardiomyopathy, or malignant cardiac dysrhythmias.
    • Orthopnea or paroxysmal nocturnal dyspnea (PNDPND):
    • Orthopnea: Dyspnea provoked in the recumbent position, relieved by sitting upright or elevating the head with pillows, characteristic of left ventricular failure causing fluid redistribution to pulmonary vasculature.
    • Paroxysmal nocturnal dyspnea: Acute, severe dyspnea awakening the individual abruptly from sleep (1−2 hours1 - 2\,\text{hours} after recumbency), requiring sitting upright for relief.
    • Ankle edema: Bilateral dependent edema indicative of systemic venous congestion resulting from right-sided heart failure, chronic venous insufficiency, or renal sodium retention; unilateral edema typically indicates local venous obstruction or lymphatic insufficiency.
    • Palpitations or tachycardia: Unpleasant awareness of forceful, irregular, or rapid heartbeats, suggesting supraventricular tachycardias, atrial fibrillation, frequent premature ventricular contractions, or severe anxiety.
    • Intermittent claudication: Reproducible cramping pain, fatigue, or discomfort localized in the musculature of the lower extremities (primarily the calves), induced by exertion and relieved by rest within 1−10 minutes1 - 10\,\text{minutes}, indicative of peripheral artery disease (PADPAD).
    • Known heart murmur: Auditory vibrations produced by turbulent intracardiac blood flow, indicating potential structural valvular lesions (aortic stenosis, mitral regurgitation) or congenital defects (ventricular septal defect).
    • Unusual fatigue or shortness of breath with usual activities: Unexplained depletion of energy or severe dyspnea provoked by mild daily tasks, serving as a primary early presentation of heart failure or progressive myocardial ischemia.
  • Clinical Features of Chest Pain:

    • Differentiating Ischemic vs. Non-Ischemic Discomfort:
    • Ischemic (Angina Pectoris): Described as deep, visceral pressure, heaviness, squeezing, fullness, or aching; located retrosternally with possible radiation to the jaw, neck, left arm, or back; provoked by physical exertion, cold temperatures, emotional stress, or heavy meals; relieved within minutes by rest or sublingual nitroglycerin; not affected by inspiration or positional shifts.
    • Non-Ischemic / Musculoskeletal / Pleuritic: Characterized by sharp, knifelike, lancinating, or pinpoint pain; changes directly with deep inspiration (pleuritic), coughing, torso rotation, or direct palpation of chest wall structures (costochondritis); may last for seconds or continuously for days without variation.
  • Red Flag Indicators of a Change in Clinical Status:

    • Progressive unstable angina: Angina occurring at rest, presenting with accelerating frequency or severity (crescendo pattern), or provoked at lower workloads.
    • Sudden onset of severe, unexplained resting dyspnea or acute orthopnea.
    • New-onset cardiac dysrhythmias (e.g., rapid sustained atrial fibrillation, multifocal ventricular ectopy, paired ventricular beats, sustained ventricular tachycardia).
    • Sudden, unexplained drop in systolic blood pressure (>10−20 mmHg> 10 - 20\,\text{mmHg}) from baseline during physical exertion or accompanied by ischemic symptoms.
    • Acute neurological deficits: Sudden facial drooping, unilateral motor weakness, sensory loss, slurred speech, or acute cognitive confusion (transient ischemic attack or stroke).
    • Acute peripheral circulatory compromise: Sudden unilateral leg pain, pallor, pulselessness, coldness, or paresthesias (acute limb ischemia).
    • Persistent dizziness, lightheadedness, presyncope, or unprovoked syncope.
    • Acute, rapid development of lower extremity pitting edema or sudden weight gain (>2−3 lbs> 2 - 3\,\text{lbs} overnight or >5 lbs> 5\,\text{lbs} in one week) indicating acute decompensated heart failure.
  • The OLDCART Symptom Assessment Framework:

    • O - Onset: Precise time, setting, and circumstances surrounding when the symptom first manifested (acute vs. gradual onset).
    • L - Location: Anatomical origin of the symptom and whether it radiates to other regions.
    • D - Duration: How long the symptom persists (seconds, minutes, continuous hours) and its pattern over time.
    • C - Characteristics: Specific qualitative description of the symptom (e.g., sharp, dull, burning, squeezing, throbbing, pressure).
    • A - Aggravating Factors: Specific actions, positions, physical movements, or environmental stimuli that exacerbate or reproduce the symptom.
    • R - Relieving Factors: Interventions, medications, bodily postures, or rest that reduce or eliminate the symptom.
    • T - Treatment: Prior medications, therapies, or self-care strategies implemented to manage the symptom and their measured degree of effectiveness.
  • SOAP Note Clinical Documentation Framework:

    • S - Subjective: Direct, qualitative narrative provided by the patient or caregiver regarding current health status, primary complaints, history of present illness (HPIHPI), symptom changes, functional limitations, and emotional or psychological factors.
    • O - Objective: Concrete, verifiable, reproducible, and measurable clinical data collected during the clinical visit; includes measured resting vital signs, anthropometric indices, physical exam findings, electrocardiographic recordings, laboratory values, exercise test data, and functional capacity metrics.
    • A - Assessment: Professional clinical synthesis, analysis, and diagnostic interpretation combining the subjective report and objective findings; incorporates the patient's current clinical stability, risk stratification category, progress toward functional goals, and differential diagnoses.
    • P - Plan: Specific therapeutic strategy developed for the patient; encompasses detailed exercise prescriptions (frequency, intensity, time, type, volume, progression - FITT-VP), modifications to medication or medical referrals, scheduling of follow-up evaluations, and educational interventions.
  • Common Medical Abbreviations:

    • c/o: Complains of (used to describe patient-reported symptoms in the subjective section).
    • d/x or dx: Diagnosis (the identified medical pathology or clinical condition).
    • f/u: Follow-up (subsequent appointments, assessments, or reassessments).
    • h/x or hx: History (past medical, surgical, or family health records).
    • HTN: Hypertension (persistently elevated systemic arterial blood pressure).
    • SOB: Shortness of breath (subjective symptom of respiratory distress or dyspnea).
    • sxs: Symptoms (subjective evidence of a disease or physical disturbance).
    • TM: Treadmill (referring to a diagnostic or therapeutic exercise modality, or alternatively tympanic membrane depending on context; primarily treadmill in cardiovascular exercise physiology).

Behavioral Psychology and Exercise Adherence

  • Transtheoretical Model of Change (TTM / Stages of Change):

    • Precontemplation:
    • Description: The individual has no current intention to adopt healthy behaviors (such as regular exercise) within the foreseeable future (typically framed as within the next 6 months).
    • Characteristics: Often uninformed or under-informed about the negative consequences of sedentary behavior, or demoralized by repeated past failures; tends to be defensive, resistant to change, and avoids processing information regarding health behaviors.
    • Contemplation:
    • Description: The individual is aware that a problem exists and is seriously considering behavior modification within the next 6 months.
    • Characteristics: Exhibits ambivalence; weighs the pros and cons of changing behavior equally (decisional balance equilibrium), which can trap them in chronic contemplation or procrastination.
    • Preparation:
    • Description: The individual intends to initiate overt behavioral change in the immediate future, usually defined as within the next 30 days.
    • Characteristics: Has developed an action plan and is taking small, preliminary behavioral steps (e.g., buying running shoes, joining a fitness facility, gathering exercise program information).
    • Action:
    • Description: The individual has made explicit, observable changes in their lifestyle and behavior within the past 6 months.
    • Characteristics: Fully engaged in the target behavior at a level that meets established public health guidelines, but requires substantial cognitive effort and vigilance; carries the highest risk of relapse.
    • Maintenance:
    • Description: The individual has sustained the target health behavior for a continuous period exceeding 6 months.
    • Characteristics: The behavior has become integrated into daily routine; the individual possesses high self-efficacy, exhibits decreased temptation to regress, and uses behavioral relapse prevention strategies.
    • Termination / Relapse Considerations:
    • Termination: The theoretical end-state wherein the individual experiences zero temptation to return to old habits and maintains 100%100\% self-efficacy across all challenging environments (rarely applied in lifestyle physical activity contexts).
    • Relapse: Regression from Action or Maintenance to an earlier stage (Contemplation or Precontemplation); recognized in TTM as a common cyclical event rather than a permanent failure, requiring reassessment of coping strategies.
  • Self-Efficacy Theory:

    • Definition: Defined by Albert Bandura as an individual's task-specific belief and confidence in their capability to execute the actions required to produce designated levels of performance.
    • Four Core Sources of Self-Efficacy (Lecture Curriculum):
    • Mastery Experiences (Past Performance Accomplishments): The most potent source of self-efficacy; successful past execution of a target behavior directly builds personal confidence, whereas early or repeated failures undermine it.
    • Vicarious Experiences (Social Modeling): Observing peer individuals with similar capabilities successfully complete a target behavior; enhances the observer's belief that they too can succeed.
    • Verbal/Social Persuasion: Credible, constructive, and realistic encouragement or feedback from respected clinical providers, exercise specialists, or peers, helping individuals overcome self-doubt.
    • Physiological and Affective States (Somatic and Emotional Arousal): How individuals interpret physical symptoms (e.g., elevated heart rate, muscle soreness, heavy breathing) and emotional responses (e.g., anxiety vs. excitement); viewing exertion as normal physiological adaptation rather than bodily danger bolsters self-efficacy.
    • Fifth Contributing Factor (Expanded Reading Curriculum):
    • Imaginal Experiences (Visualization / Mental Simulation): The systematic cognitive practice of visualizing oneself successfully executing a challenging task or overcoming anticipated behavioral obstacles, reinforcing neural patterns and cognitive readiness before actual physical performance.
  • Self-Determination Theory (SDT):

    • Core Tenet: Focuses on the degree to which human behavior is self-motivated and self-determined, positing that human flourishing requires satisfaction of three basic psychological needs.
    • Three Basic Psychological Needs:
    • Autonomy: The universal need to feel in control of one's own choices, behaviors, and destiny, acting in accordance with personal values rather than external coercion.
    • Competence: The need to experience mastery, develop effective capabilities, and achieve desired outcomes within one's environment.
    • Relatedness: The need to feel a secure sense of belonging, connection, and mutual care with other people and social communities.
    • The Motivation Continuum:
    • Amotivation: Total absence of motivation, intentionality, or value regarding the target behavior.
    • Extrinsic Motivation:
      • External Regulation: Behavior driven solely by external rewards or avoiding punishment.
      • Introjected Regulation: Behavior driven by internal pressures to avoid guilt, shame, or preserve ego/self-worth.
      • Identified Regulation: Behavior accepted as personally important and valuable, though not inherently enjoyable.
      • Integrated Regulation: The behavior is fully assimilated with the individual's core identity, values, and lifestyle.
    • Intrinsic Motivation: Engaging in an activity purely for the inherent pleasure, satisfaction, stimulation, and enjoyment of the behavior itself.
  • Practical Strategies to Facilitate Behavior Change:

    • SMART Goal Setting: Collaborative development of Specific, Measurable, Action-oriented, Realistic, and Time-bound objectives.
    • Self-Monitoring: Systematic use of tracking mechanisms (activity logs, heart rate monitors, pedometers, mobile applications) to create self-awareness and track objective progress.
    • Stimulus Control: Environmental engineering to remove triggers that prompt sedentary behavior and add prominent cues that encourage physical activity (e.g., placing workout clothes by the front door).
    • Decisional Balance Interventions: Assisting patients in listing and prioritizing the personal pros and cons of changing their behavior, systematically bolstering perceived benefits while mitigating perceived barriers.
    • Relapse Prevention Planning: Identifying high-risk situations (vacation, illness, inclement weather, busy work schedules) and formulating proactive "if-then" coping strategies to maintain behavioral continuity.

General Pharmacokinetics and Pharmacodynamics

  • Pharmacokinetics:

    • Definition: The quantitative study of what the biological organism does to a drug over time, detailing its physiological transit and disposition.
    • The ADME Model:
    • A - Absorption:
      • Definition: The movement of a pharmaceutical compound from its site of administration across biological membranes into systemic circulation.
      • Mechanisms: Passive diffusion, facilitated diffusion, active transport, and pinocytosis.
      • Influencing Factors: Bioavailability (FF—the percentage of unchanged drug reaching the systemic circulation), route of administration, gastric emptying time, lipid solubility, and local tissue blood flow.
    • D - Distribution:
      • Definition: The reversible transfer of a drug between the systemic circulation and peripheral tissues, organs, and intracellular compartments.
      • Influencing Factors: Regional blood flow, capillary permeability, tissue-specific affinity, plasma protein binding (primarily to human serum albumin, where only the unbound or "free" fraction is biologically active), and the physiological Volume of Distribution (VdV_d).
    • M - Metabolism (Biotransformation):
      • Definition: The biochemical enzymatic alteration of a drug within the body, primarily converting lipophilic compounds into hydrophilic metabolites to facilitate elimination.
      • Primary Site: The liver, utilizing the Cytochrome P450 (CYP450CYP450) enzyme superfamily.
      • Enzymatic Phases:
      • Phase I Reactions: Non-synthetic modifications (oxidation, reduction, hydrolysis) to introduce or expose polar functional groups.
      • Phase II Reactions: Synthetic conjugation reactions (glucuronidation, sulfation, acetylation) that attach endogenous polar molecules, inactivating the compound and facilitating excretion.
      • First-Pass Metabolism: Extensive clearance and degradation of an orally administered drug within the gastrointestinal tract and liver before it reaches the systemic circulation, substantially reducing oral bioavailability.
    • E - Excretion:
      • Definition: The irreversible removal of unchanged parent drug or inactive metabolites from the body.
      • Primary Organs: The kidneys via renal excretion (glomerular filtration, active tubular secretion, and passive tubular reabsorption); secondary routes include the hepatobiliary tract (fecal elimination via bile), lungs (expired gases), sweat, and breast milk.
      • Metric: Renal clearance and biological elimination half-life (t1/2t_{1/2}), defined as the time required for the plasma drug concentration to decrease by 50%50\%.
  • Pharmacodynamics:

    • Definition: The study of what a drug does to the body, including biochemical, cellular, and physiological mechanisms of action, receptor interactions, and the resulting dose-response relationships.
    • Agonist vs. Antagonist Pharmacodynamics:
    • Agonist: A chemical ligand or pharmaceutical agent that binds selectively to a specific receptor, induces a conformational change, and initiates a downstream intracellular biological response (exhibits both affinity and intrinsic efficacy).
    • Antagonist: An agent that binds selectively to a specific receptor with high affinity but lacks intrinsic efficacy; it prevents endogenous agonists or other drugs from binding, thereby blocking or dampening the biological response (competitive vs. non-competitive inhibition).
  • Fundamental Principles of Medication Action:

    • Routes of Drug Administration:
    • Enteral: Involves the gastrointestinal tract; includes Oral (POPO), Sublingual (SLSL, bypassing first-pass hepatic metabolism), Buccal, and Rectal (PRPR).
    • Parenteral: Involves non-alimentary delivery bypassing the gastrointestinal tract; includes Intravenous (IVIV, rapid onset with 100%100\% bioavailability), Intramuscular (IMIM), Subcutaneous (SCSC), and Intra-arterial.
    • Topical and Transdermal: Application to cutaneous or mucosal surfaces; transdermal patches deliver steady systemic absorption over prolonged periods.
    • Inhalation: Rapid local or systemic delivery via pulmonary capillary beds.
    • Generic vs. Brand Name Medications:
    • Active Pharmaceutical Ingredient (APIAPI): Identical chemical structure, strength, dosage form, and route of administration between generic and brand name formulations.
    • Inactive Ingredients (Excipients): Generic drugs may differ in binding agents, colorings, flavorings, preservatives, and capsule matrices.
    • Bioequivalence Standard: Generic formulations must demonstrate that the rate and extent of systemic absorption do not differ significantly (±20%\pm 20\% margin or 80%−125%80\% - 125\% confidence interval for AUCAUC and peak concentration) compared to the pioneer brand-name product.
    • Temporal Parameters of Drug Action:
    • Onset of Action: The time required following drug administration for the plasma concentration to cross the Minimum Effective Concentration (MECMEC) and elicit a detectable therapeutic response.
    • Peak Effect: The time point at which the drug reaches its maximum plasma concentration (CmaxC_{max}), eliciting its greatest pharmacological impact.
    • Duration of Action: The total length of continuous time during which the plasma drug concentration remains at or above the MECMEC.
    • Therapeutic Window and Therapeutic Index (TITI):
    • Therapeutic Window: The clinical plasma concentration range bounded below by the Minimum Effective Concentration (MECMEC) and bounded above by the Minimum Toxic Concentration (MTCMTC).
    • Clinical Implication: Medications with a wide therapeutic window are generally safer; agents with a narrow therapeutic window (e.g., Digoxin, Warfarin, Lithium) require precise therapeutic drug monitoring to prevent toxicity while maintaining therapeutic efficacy.

Cardiovascular Pharmacology and Major Drug Classes for CAD Risk Factors

  • Beta-Adrenergic Receptor Blockers (Beta-Blockers):

    • Mechanism of Action: Competitively bind to and inhibit β1\beta_1-adrenergic receptors in cardiac tissue (cardioselective) and/or β2\beta_2-receptors in vascular/bronchial smooth muscle (non-selective); antagonize circulating catecholamines (epinephrine and norepinephrine), decreasing adenylyl cyclase activity and reducing cyclic adenosine monophosphate (cAMPcAMP).
    • Primary Indications: Hypertension, stable angina pectoris, post-myocardial infarction secondary prevention, tachyarrhythmias, and stable heart failure (HFrEFHFrEF).
    • Representative Generic and Brand Names:
    • Metoprolol tartrate (Lopressor)
    • Metoprolol succinate (Toprol-XL)
    • Atenolol (Tenormin)
    • Propranolol (Inderal - non-selective)
    • Carvedilol (Coreg - combined α1\alpha_1 and β\beta blocker)
    • Adverse Side Effects: Sinus bradycardia, atrioventricular (AVAV) conduction blocks, fatigue, lethargy, cold extremities, bronchospasm in reactive airway disease, erectile dysfunction, and masking the sympathetic warning symptoms of hypoglycemia (tachycardia, tremors) in patients with diabetes.
    • Exercise and Hemodynamic Effects: Significantly blunts resting and maximal exercise heart rate and systolic blood pressure; reduces MVO2MVO_2; necessitates relying on the Borg Rating of Perceived Exertion (RPERPE) rather than target heart rate formulas for exercise prescription.
  • HMG-CoA Reductase Inhibitors (Statins):

    • Mechanism of Action: Competitively inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG−CoAHMG-CoA) reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis; the resulting drop in intracellular cholesterol upregulates hepatic low-density lipoprotein (LDLLDL) receptors, accelerating the clearance of circulating atherogenic LDLLDL particles; also exert pleiotropic effects (plaque stabilization, improved endothelial function, reduced vascular inflammation).
    • Primary Indications: Hypercholesterolemia, primary and secondary prevention of atherosclerotic cardiovascular events, and familial hyperlipidemia.
    • Representative Generic and Brand Names:
    • Atorvastatin (Lipitor)
    • Simvastatin (Zocor)
    • Rosuvastatin (Crestor)
    • Pravastatin (Pravachol)
    • Adverse Side Effects: Statin-associated muscle symptoms (SAMSSAMS) including myalgia, myositis, weakness, and rarely rhabdomyolysis (marked by elevated creatine kinase and myoglobinuria); hepatotoxicity (elevated transaminases); and mild risk of increased blood glucose levels.
  • Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors):

    • Mechanism of Action: Competitively inhibit the angiotensin-converting enzyme, preventing the conversion of Angiotensin I to the potent vasoconstrictor Angiotensin II; reduces circulating aldosterone secretion, decreasing renal sodium and water retention; inhibits the degradation of bradykinin, promoting systemic vasodilation.
    • Primary Indications: Hypertension, chronic heart failure with reduced ejection fraction, post-myocardial infarction remodeling attenuation, and diabetic nephropathy.
    • Representative Generic and Brand Names:
    • Lisinopril (Prinivil, Zestril)
    • Enalapril (Vasotec)
    • Ramipril (Altace)
    • Captopril (Capoten)
    • Adverse Side Effects: Persistent, non-productive dry cough (caused by pulmonary bradykinin accumulation); hyperkalemia (due to reduced aldosterone); symptomatic hypotension/orthostasis; acute renal failure in bilateral renal artery stenosis; and angioedema (potentially life-threatening swelling of the lips, tongue, and pharynx).
  • Angiotensin II Receptor Blockers (ARBs):

    • Mechanism of Action: Selectively block the Angiotensin II Type 1 (AT1AT_1) receptor on vascular smooth muscle and adrenal cortex cells, blocking Angiotensin II-mediated vasoconstriction, aldosterone release, and vascular remodeling without altering bradykinin metabolism.
    • Primary Indications: Hypertension, heart failure, and diabetic nephropathy, especially in patients who cannot tolerate ACE inhibitors due to persistent cough.
    • Representative Generic and Brand Names:
    • Losartan (Cozaar)
    • Valsartan (Diovan)
    • Olmesartan (Benicar)
    • Irbesartan (Avapro)
    • Adverse Side Effects: Hyperkalemia, dizziness, orthostatic hypotension, renal functional impairment; minimal risk of dry cough or angioedema relative to ACE inhibitors.
  • Calcium Channel Blockers (CCBs):

    • Mechanism of Action: Inhibit voltage-dependent L-type calcium channels in vascular smooth muscle and cardiac myocytes, reducing intracellular calcium influx during depolarization; this causes systemic and coronary arteriolar vasodilation, reduces afterload, and decreases myocardial contractility and nodal conduction.
    • Subclasses:
    • Dihydropyridines: Primarily affect vascular smooth muscle; potent vasodilators with minimal direct effect on cardiac conduction.
      • Amlodipine (Norvasc)
      • Nifedipine (Procardia, Adalat CC)
      • Felodipine (Plendil)
    • Non-Dihydropyridines: Directly affect myocardium and nodal tissues; reduce heart rate, depress AV nodal conduction velocity, and decrease contractility.
      • Diltiazem (Cardizem, Tiazac)
      • Verapamil (Calan, Verelan)
    • Adverse Side Effects:
    • Dihydropyridines: Peripheral dependent edema (ankle edema), reflex tachycardia, lightheadedness, headache, and cutaneous flushing.
    • Non-Dihydropyridines: Bradycardia, AV nodal conduction blocks, worsening of heart failure, and severe constipation (particularly with Verapamil).
  • Diuretics:

    • Mechanism of Action: Inhibit specific renal tubular sodium reabsorption pathways, promoting natriuresis and diuresis; reduces intravascular blood volume, lowers venous return (preload), and reduces systemic blood pressure.
    • Subclasses:
    • Thiazide Diuretics: Inhibit the Na+/Cl−Na^{+}/Cl^{-} cotransporter in the early distal convoluted tubule; first-line therapy for uncomplicated hypertension.
      • Hydrochlorothiazide or HCTZHCTZ (Microzide)
      • Chlorthalidone (Hygroton)
    • Loop Diuretics: Inhibit the Na+/K+/2Cl−Na^{+}/K^{+}/2Cl^{-} cotransporter in the thick ascending limb of the loop of Henle; potent natriuresis used for volume overload.
      • Furosemide (Lasix)
      • Bumetanide (Bumex)
    • Potassium-Sparing Diuretics / Aldosterone Antagonists: Inhibit epithelial sodium channels (ENaCENaC) or competitively antagonize mineralocorticoid receptors in the collecting duct; prevent potassium excretion.
      • Spironolactone (Aldactone)
      • Triamterene (Dyrenium)
    • Adverse Side Effects: Hypokalemia (thiazides and loop diuretics, predisposing patients to cardiac dysrhythmias), hyperkalemia (potassium-sparing diuretics), dehydration, volume depletion, orthostatic hypotension, hyponatremia, and hyperuricemia (which can trigger gout).
  • Organic Nitrates:

    • Mechanism of Action: Denitrated to form free radical nitric oxide (NONO) inside vascular smooth muscle cells, which activates guanylyl cyclase, increasing cyclic guanosine monophosphate (cGMPcGMP); this dephosphorylates myosin light chains, causing smooth muscle relaxation.
    • Hemodynamic Effect: Causes prominent systemic venodilation (reducing venous return, end-diastolic volume, and ventricular preload), which lowers myocardial wall stress and MVO2MVO_2; also dilates large epicardial coronary vessels to redistribute collateral flow to ischemic myocardium.
    • Primary Indications: Acute treatment and prophylaxis of angina pectoris.
    • Representative Formulations:
    • Nitroglycerin (Nitrostat - sublingual tablet, Nitro-Bid - transdermal, Nitro-Dur - patch)
    • Isosorbide mononitrate (Imdur)
    • Isosorbide dinitrate (Isordil)
    • Adverse Side Effects: Throbbing vascular headache, significant postural hypotension, reflex tachycardia, syncope, and the rapid development of pharmacological tolerance (requiring a daily nitrate-free interval of 10−12 hours10 - 12\,\text{hours}).
    • Contraindication: Absolute contraindication with phosphodiesterase-5 (PDE−5PDE-5) inhibitors (e.g., Sildenafil, Tadalafil) due to the risk of severe, life-threatening systemic hypotension.
  • Antiplatelet Agents:

    • Mechanism of Action: Inhibit platelet activation and aggregation cascades to prevent arterial thrombus formation on ruptured atherosclerotic plaques.
    • Representative Formulations:
    • Aspirin (Acetylsalicylic Acid): Irreversibly inhibits the cyclooxygenase-1 (COX−1COX-1) enzyme, preventing the production of thromboxane A2A_2 (TXA2TXA_2), a potent platelet aggregator and vasoconstrictor.
    • Clopidogrel (Plavix): Irreversibly blocks the adenosine diphosphate (ADPADP) receptor subtype P2Y12P2Y_{12} on the platelet surface, preventing subsequent activation of the glycoprotein GPIIb/IIIaGPIIb/IIIa complex.
    • Primary Indications: Secondary prevention of myocardial infarction, acute coronary syndromes, post-percutaneous coronary intervention (PCIPCI) with stent placement, and ischemic stroke.
    • Adverse Side Effects: Increased risk of bleeding, gastrointestinal irritation, ulceration, and easy bruising.